Cian Healthcare Ltd (CHCL) — shareholding pattern, promoter holding, financials and share price
About Cian Healthcare Ltd (CHCL)
Cian Healthcare Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CHCL and on the BSE under scrip code 542678. Its ISIN is INE05BN01027.
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products. [1]
Cian Healthcare Limited is a WHO-GMP & ISO-9001:2015 certified company that manufactures a wide range of pharmaceutical, nutraceutical, ayurvedic, cosmeceuticals, sexual wellness, and food supplement products.
It operates under various business models including brand business, export, third-party manufacturing, and government supplies.
Listed peers in Pharmaceuticals: Venmax Drugs & Pharmaceuticals Ltd, Ishita Drugs & Industries Ltd, Centuple Global Ltd, Rekvina Labs Ltd, Mono Pharmacare Ltd, Desh Rakshak Aushdhalaya Ltd.
Valuation & Returns
At ₹9.55 a share, Cian Healthcare Ltd (CHCL) was valued at a price-to-book of 2.54x on a book value of ₹3.42 per share. Solomo computes return on equity of -117.84% and return on capital employed of -25.84% from filed results.
- Industry P/E
- 36.41x
- P/B
- 2.54x
- Book value / share
- ₹3.42
- ROE
- -117.84%
- ROCE
- -25.84%
- ROA
- -37.84%
- Debt / equity
- 3.36x
- Dividend yield
- 0%
- EBITDA margin
- -67.31%
- 52-week range
- ₹3.11 – ₹8.67
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Cian Healthcare Ltd (CHCL) reported revenue of ₹28 crore, net profit of ₹-23 crore and earnings per share of ₹-9.32. That compares with revenue of ₹31 crore and net profit of ₹-26 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹17 crore and net profit ₹-18 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 78 | 69 | 62 | 31 | 28 |
| Net profit (₹ cr) | -6 | 2 | 1 | -26 | -23 |
| EPS (₹) | -2.21 | 0.81 | 0.34 | -10.39 | -9.32 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -4.63% | -11.55% | -21.61% | -50.08% |
| Stock price CAGR | - | -16% | -29% | 145% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 95% of Cian Healthcare Ltd (CHCL). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2019.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 95% | - | - | - | 5% |
| Sep 2025 | 27.1% | 34.5% | - | - | 72.9% |
| Mar 2025 | 27.1% | 34.5% | - | - | 72.9% |
| Sep 2024 | 27.1% | 34.5% | - | - | 72.9% |
| Jun 2024 | 27.1% | 99.9% | - | - | 72.9% |
| Mar 2024 | 27.1% | 47.8% | - | - | 72.9% |
| Sep 2023 | 49.62% | 18.8% | - | - | 50.38% |
| Mar 2023 | 51.85% | 18% | - | - | 48.15% |